Opendata, web and dolomites

EyeTREAT SIGNED

Innovative tool for personalized treatment of patients with neovascular age-macular degeneration: dosage optimization for long term efficacy treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EyeTREAT project word cloud

Explore the words cloud of the EyeTREAT project. It provides you a very rough idea of what is the project "EyeTREAT" about.

effect    clinical    25    pioneer    health    centre    imaging    intervals    eye    vegf    million    with    injection    determinations    2040    oct    tomography    intravitreal    optimization    pharmacokinetic    computational    instance    first    almost    rest    clinics    anticipated    reducing    regimen    tool    linking    thickness    benefit    constitute    invasively    burden    varies    threatening    patient    frequency    injections    scan    anti    efficient    visual    coherence    treatment    life    manchester    europeans    disciplinary    illnesses    drug    ophthalmic    therapeutic    technique    retina    character    care    appropriate    renowned    pharmacodynamic    optical    quality    degeneration    personalization    university    individual    age    amd    combining    consists    expertise    dosing    missing    ocular    vitreous    regular    clear    consensus    macular    definitely    quantitative    career    treatments    sectoral    eylea    ageing    population    tools    patients    ball    avastin    central    researcher    candidate    inter    lucentis    lasting    dose    measuring    individualized    models   

Project "EyeTREAT" data sheet

The following table provides information about the project.

Coordinator
THE UNIVERSITY OF MANCHESTER 

Organization address
address: OXFORD ROAD
city: MANCHESTER
postcode: M13 9PL
website: www.manchester.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website https://www.research.manchester.ac.uk/portal/evamaria.delamo.html
 Total cost 122˙159 €
 EC max contribution 122˙159 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE UNIVERSITY OF MANCHESTER UK (MANCHESTER) coordinator 122˙159.00

Map

 Project objective

With the ageing population, visual threatening illnesses are increasing. For instance, age-related macular degeneration (AMD) is expected to affect almost 25 million Europeans by 2040. The AMD treatment consists in regular injections of the anti-VEGF therapeutic drug (Lucentis, Avastin, Eylea) into the eye ball, vitreous, for the rest of the patient life. However, the dosing intervals varies widely among the patients and there is no a clear consensus or quantitative method for evaluating the injection frequency. For that, computational tools linking the drug dose regimen and the drug effect in the retina are needed. However, such pharmacokinetic-pharmacodynamic models are still missing. Combining population pharmacokinetic and optical coherence tomography (OCT) imaging technique is a new, novel and promising approach. The drug effect can be evaluated non-invasively, measuring the central macular thickness in the retina scan. The models generated will allow appropriate individualized dosing regimen to the patients in clinics that will be anticipated from individual retina scan determinations with OCT. The optimization and personalization of dosing regimen will ensure an efficient long-lasting treatment, improving patient quality of life while reducing the burden to the health care system. Moreover, the models will increase our understanding in the treatments, constitute a pioneer tool in effect assessment in ocular therapeutic field and a first step towards more advanced ophthalmic models. The candidate has strong expertise in intravitreal pharmacokinetic and this project will advance her into clinical pharmacodynamic modelling at the renowned Centre for Applied Pharmacokinetic Research, University of Manchester. The inter-disciplinary and inter-sectoral character of the project will definitely benefit her career development as a researcher.

 Publications

year authors and title journal last update
List of publications.
2019 Astrid Subrizi, Eva M. del Amo, Viktor Korzhikov-Vlakh, Tatiana Tennikova, Marika Ruponen, Arto Urtti
Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties
published pages: 1446-1457, ISSN: 1359-6446, DOI: 10.1016/j.drudis.2019.02.001
Drug Discovery Today 24/8 2020-04-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EYETREAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EYETREAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

Widow Spider Mating (2020)

Immature mating as a novel tactic of an invasive widow spider

Read More  

TARGET SLEEP (2020)

Boosting motor learning through sleep and targeted memory reactivation in ageing and Parkinson’s disease

Read More  

ASIQS (2019)

Antiferromagnetic spintronics investigated by quantum sensing techniques

Read More